Necrosulfonamide
| Code | Size | Price |
|---|
| AG-CR1-3705-M005 | 5 mg | £55.00 |
Quantity:
| AG-CR1-3705-M025 | 25 mg | £190.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Shipping:
Ambient
Storage:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
NSA; (2E)-N-[4-[[(3-Methoxy-2-pyrazinyl)amino]sulfonyl]phenyl]-3-(5-nitro-2-thienyl)-2-propenamide
Appearance:
Off-white to yellow solid.
CAS:
1360614-48-7
EClass:
32160000
Form (Short):
liquid
Handling Advice:
Keep cool and dry.Protect from light.
InChi:
InChI=1S/C18H15N5O6S2/c1-29-18-17(19-10-11-20-18)22-31(27,28)14-6-2-12(3-7-14)21-15(24)8-4-13-5-9-16(30-13)23(25)26/h2-11H,1H3,(H,19,22)(H,21,24)/b8-4+
InChiKey:
FNPPHVLYVGMZMZ-XBXARRHUSA-N
Long Description:
Chemical. CAS: 1360614-48-7. Formula: C18H15N5O6S2. MW: 461.5. Inhibitor of necroptosis, by blocking mixed lineage kinase domain-like protein (MLKL), a key substrate of receptor-interacting serine-threonine kinase 3 (RIP3). Shown to prevent the MLKL-RIP1-RIP3 necrosome complex from interacting with downstream necrosis effectors. Potent inhibitor of Gasdermin D that works well for mice studies. It binds directly to Gasdermin D and inhibits the oligomerization of the N-terminus and therefore the pore formation and pyroptosis. Displayed neuroprotective effects after ischemic brain injury, prevented cystine-starvation-induced necroptosis and ferroptosis in human triple negative breast cancer cells and rescued cells from TLR3 ligand-induced death.
MDL:
MFCD02370191
Molecular Formula:
C18H15N5O6S2
Molecular Weight:
461.5
Package Type:
Vial
Product Description:
Inhibitor of necroptosis, by blocking mixed lineage kinase domain-like protein (MLKL), a key substrate of receptor-interacting serine-threonine kinase 3 (RIP3). Shown to prevent the MLKL-RIP1-RIP3 necrosome complex from interacting with downstream necrosis effectors. Potent inhibitor of gasdermin D that works well for mice studies. It binds directly to gasdermin D and inhibits the oligomerization of the N-terminus and therefore the pore formation and pyroptosis. Displayed neuroprotective effects after ischemic brain injury, prevented cystine-starvation-induced necroptosis and ferroptosis in human triple negative breast cancer cells and rescued cells from TLR3 ligand-induced death.
Purity:
>95%
SMILES:
O=C(/C=C/C1=CC=C([N+]([O-])=O)S1)NC2=CC=C(S(NC3=C(OC)N=CC=N3)(=O)=O)C=C2
Solubility Chemicals:
Soluble in DMSO (20mg/ml) or DMF (20mg/ml). Insoluble in water.
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase: L. Sun, et al.; Cell 148, 213 (2012) | Necrosulfonamide inhibits necroptosis by selectively targeting the mixed lineage kinase domain-like protein: D. Liao, et al. Med. Chem. Commun. 5, 333 (2014) | The degradation of mixed linage kinase domain-like protein promotes neuroprotection after ischemic brain injury: Y. Zhou, et al.; Oncotarget 8, 68393 (2017) | CHAC1 degradation of glutathione enhances cysteine-starvation-induced necroptosis and ferroptosis in human triple negative breast cancer cells via the GCN2-elF2alpha-ATF4 pathway: M.S. Chen, et al.; Oncotarget 8, 114588 (2017) | Activated platelets induce MLKL-driven neutrophil necroptosis and release of neutrophil extracellular traps in venous thrombosis: D. Nakazawa, et al.; Cell Death Discov. 5, (2018) | Necrosulfonamide attenuates spinal cord injury via necroptosis inhibition: Y. Wang, et al.; World Neurosurg. 114, e1186 (2018) | Chemical disruption of the pyroptotic pore-forming protein gasdermin D inhibits inflammatory cell death and sepsis: J.K. Rathkey, et al.; Sci. Immunol. 3, eaat2738 (2018) | Biallelic RIPK1 mutations in humans cause severe immunodeficiency, arthritis, and intestinal inflammation: D. Cuchet-Lourenco, et al.; Science 361, 810 (2018)